Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Severe COVID-19
NCT04922827Phase 2Completed
- Sponsor
- Universitätsklinikum Jena
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Infliximab + Standard of Care with Standard of Care (2 arms). Primary endpoint: 28-day mortality. Started Jun 2021; status: completed.
02
Drugs
infliximab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04922827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922827.